SLC5A2 and gout: First, for subgroup analysis of individuals younger than 65 years, SGLT2 inhibitor users had a significantly lower risk of gout (HR, 0.83; 95% CI, 0.76-0.90), but there was no association between SGLT2 inhibitor use and gout for those aged 65 years or older.